CAS: 1137868-52-0; 4-((9-Cyclopentyl-7,7-Difluoro-5-Methyl-6-Oxo-6,7,8,9-Tetrahydro-5H-Pyrimido[4,5-B][1,4]Diazepin-2-yl)Amino)-2-Fluoro-5-Methoxy-N-(1-Methylpiperidin-4-yl)Benzamide

上下游产品

4-(9-Cyclopentyl-7,7-Difluoro-5-Methyl-6-Oxo-6,7,8,9-Tetrahydro-5H-Pyrimido[4,5-B][1,4]Diazepin-2-Ylamino)-2-Fluoro-5-Methoxy-Benzoic Acid 1137867-66-3
2-Chloro-9-Cyclopentyl-7,7-Difluoro-5-Methyl-5,7,8,9-Tetrahydro-6H-Pyrimido[4,5-B][1,4]Diazepin-6-One 1062246-03-0
2-Chloro-9-Cyclopentyl-7,7-Difluoro-5,7,8,9-Tetrahydro-Pyrimido[4,5-B][1,4]Diazepin-6-One 1062246-01-8
3-[(2-Chloro-5-Nitro-Pyrimidin-4-yl)-Cyclopentyl-Amino]-2,2-Difluoro-Propanoic Acid Ethyl Ester 1062245-99-1

📜3-Cyclopentylamino-2,2-Difluoro-Propanoic Acid Ethyl Ester置于盐酸,铁粉,碳酸氢钠,O-Benzotriazol-1-Yl-N,N,N',N'-Bis(Tetramethylene)Uronium Hexafluorophosphate,Caesium Carbonate,溶剂黄146,N,N-二异丙基乙胺体系中,用 乙醇,水,乙酸乙酯,N,N-二甲基甲酰胺 用作溶剂,化学反应 53.0H,反应生成Tak960抑制剂
参考文献:Identification Of Novel,Potent And Selective Inhibitors Of Polo-Like Kinase 1
标题:Identification Of Novel,Potent And Selective Inhibitors Of Polo-Like Kinase 1
摘要:A Series Of Pyrimidodiazepines Was Identified As Potent Polo-Like Kinase 1 (Plk1) Inhibitors. The Synthesis And Sar Are Discussed. The Lead Compound 7 (Ro3280) Has Potent Inhibitory Activity Against Plk1,Good Selectivity Against Other Kinases,And Excellent In Vitro Cellular Potency. It Showed Strong Antitumor Activity In Xenograft Mouse Models. (C) 2011 Elsevier Ltd. All Rights Reserved.
Doi:10.1016/j.Bmcl.2011.11.052

专利信息

专利号:US-8003785-B2
优先权日:2008-06-18
标 题 :Halo-substituted pyrimidodiazepines
发明人：CAI JIANPING; CHEN SHAOQING; CHU XIN-JIE; LUK KIN-CHUN; MISCHKE STEVEN GREGORY; SUN HONGMAO; WOVKULICH PETER MICHAEL
权利人:TAKEDA PHARMACEUTICAL
摘要:The present invention provides PLK1 inhibitor compounds of formula I: n nuseful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas. Also provided are intermediate compounds useful in the synthesis of compounds of formula I.

专利号:EP-2878592-B1
优先权日:2013-11-27
标题 :Synthesis of amide derivatives of some nonsteroidal antiinflammatory drugs as potential pro-drugs
发明人：KÃœCÃœKGÃœZEL ILKAY; KULABAS NECLA; SET IREM
权利人:KUECUEKGUEZEL ILKAY

专利号:EP-2878592-A1
优先权日:2013-11-27
标题 :Synthesis of amide derivatives of some nonsteroidal antiinflammatory drugs as potential pro-drugs

专利号:WO-2012100179-A1
优先权日:2011-01-21
标题:Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives

专利号:US-2012009151-A1
优先权日:2007-12-21
标题 :Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof
发明人：HAN AMY QI; COBURN GLEN A; PROVONCHA KATHLEEN P; ROTSHTEYN YAKOV
权利人:HAN AMY QI; COBURN GLEN A; PROVONCHA KATHLEEN P; ROTSHTEYN YAKOV; PROGENICS PHARM INC
摘要:Disclosed herein are novel triazines and related compounds, the synthesis thereof, and compositions, including pharmaceutical compositions, comprising the novel triazines and related compounds. Such novel triazines and related compounds function to inhibit or block entry of viruses of the Flaviviridae family, including Hepatitis C virus (HCV), into cells that are susceptible to virus infection. These compounds are useful for the treatment, therapy and/or prophylaxis of viral diseases and infection, including HCV infection.

专利号:US-2010160351-A1
优先权日:2008-12-19
标题:Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
发明人：JENKINS HELEN; KITT MICHAEL; PEARLMAN RODNEY; SERAFINI TITO; THORSETT EUGENE
权利人:NUON THERAPEUTICS INC
摘要:Disclosed is a pharmaceutical composition comprising (a) a first therapeutic agent, wherein the first therapeutic agent is a compound of formula II: n n n n n n n n n n n n or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , X and n are as defined herein; (b) a second therapeutic agent, wherein the second therapeutic agent is a uric acid synthesis inhibitor or a uricosuric agent; and (c) a pharmaceutically acceptable diluent or carrier.